ClinicalTrials.gg
CompletedNCT02400307Updated Oct 11, 2019Results posted

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

A Phase 1 interventional study of Bictegravir in HIV, sponsored by Gilead Sciences. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-11.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral bictegravir (formerly GS-9883) in adults with impaired renal function relative to matched, healthy controls with normal renal function. Each participant in the renal impairment groups will be matched for age (± 10 years), gender, and body mass index [BMI (± 20%, 18 ≤ BMI ≤ 40 kg/m\^2)] with a participant in the control group.

02

Conditions studied

  • HIV

Keywords

  • Phase 1
  • Renally Impaired
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • All Individuals:

    • Must have a calculated from 18 to 40 kg/m\^2, inclusive, at screening
  • Individuals with impaired renal function

    • Chronic stable renal impairment without recent clinical change

      • Mild: (CrCl) = 60 - 89 mL/min
      • Moderate: CrCl = 30 - 59 mL/min
      • Severe: CrCl = 15 - 29 mL/min
  • Healthy individuals

    • CrCl ≥ 90 mL/min

Key Exclusion Criteria:

  • All Individuals:

    • Pregnant or lactating females
    • positive or chronic infected
  • Individuals with impaired renal function

    • Chronic liver disease
    • Dialysis or anticipated use of dialysis
    • Renal transplant

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Severe Renal Impairment

    Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.

    Drug: Bictegravir

  • Experimental
    Moderate Renal Impairment

    Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.

    Drug: Bictegravir

  • Experimental
    Mild Renal Impairment

    Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.

    Drug: Bictegravir

Interventions

  • 75 mg tablet administered orally

    Also known as: GS-9883

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)

    AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

  2. PK Parameter: AUCinf of Bictegravir (Free)

    Free AUCinf was calculated based on unbound plasma bictegravir (AUCinf × percentage unbound bictegravir ÷ 100 for each participant).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

  3. PK Parameter: AUClast of Bictegravir (Total)

    AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

  4. PK Parameter: AUClast of Bictegravir (Free)

    Free AUClast was calculated based on unbound plasma bictegravir (AUClast × percentage unbound bictegravir ÷ 100 for each participant).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

  5. PK Parameter: Cmax of Bictegravir (Total)

    Cmax is defined as the maximum observed plasma concentration of drug.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

  6. PK Parameter: Cmax of Bictegravir (Free)

    Free Cmax was calculated based on unbound plasma bictegravir (Cmax × percentage unbound bictegravir ÷ 100 for each participant).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1

Secondary outcomes

  1. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) are defined as any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

    Time frame: First dose date to Day 31

  2. Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities

    A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment and occurring after the predose visit and on or before the date of the administration of study drug plus 30 days. The most severe graded abnormality from all tests was counted for each participant. Toxicity grade was defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening.

    Time frame: First dose date to Day 31

07

Results

Posted Oct 11, 2019

Participant flow

Participants were enrolled at study sites in the United States and New Zealand. The first participant was screened on 17 April 2015. The last study visit occurred on 13 July 2015.

Participant flow — Overall Study
MilestoneSevere Renal ImpairmentNormal Renal Function
Started118
Completed108
Not completed10
Withdrew: Enrolled and never dosed10

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)

AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)
h*ng/mLSevere Renal ImpairmentNormal Renal Function
Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total)138169.7 ± 61291.27170105.6 ± 42213.18
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Geometric least-square mean (glsm) ratio: 72.63 · 90% CI 48.80 to 108.10
PrimaryPK Parameter: AUCinf of Bictegravir (Free)

Free AUCinf was calculated based on unbound plasma bictegravir (AUCinf × percentage unbound bictegravir ÷ 100 for each participant).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUCinf of Bictegravir (Free)
h*ng/mLSevere Renal ImpairmentNormal Renal Function
PK Parameter: AUCinf of Bictegravir (Free)830.6 ± 266.59824.5 ± 203.49
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Glsm ratio: 99.29 · 90% CI 79.49 to 124.04
PrimaryPK Parameter: AUClast of Bictegravir (Total)

AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of Bictegravir (Total)
h*ng/mLSevere Renal ImpairmentNormal Renal Function
PK Parameter: AUClast of Bictegravir (Total)136956.4 ± 60557.34168876.8 ± 41706.37
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Glsm ratio: 72.43 · 90% CI 48.54 to 108.07
PrimaryPK Parameter: AUClast of Bictegravir (Free)

Free AUClast was calculated based on unbound plasma bictegravir (AUClast × percentage unbound bictegravir ÷ 100 for each participant).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUClast of Bictegravir (Free)
h*ng/mLSevere Renal ImpairmentNormal Renal Function
PK Parameter: AUClast of Bictegravir (Free)822.5 ± 263.22818.6 ± 201.18
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Glsm ratio: 99.02 · 90% CI 79.24 to 123.74
PrimaryPK Parameter: Cmax of Bictegravir (Total)

Cmax is defined as the maximum observed plasma concentration of drug.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Bictegravir (Total)
ng/mLSevere Renal ImpairmentNormal Renal Function
PK Parameter: Cmax of Bictegravir (Total)5977.0 ± 2079.577227.5 ± 2135.56
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Glsm ratio: 80.32 · 90% CI 59.56 to 108.30
PrimaryPK Parameter: Cmax of Bictegravir (Free)

Free Cmax was calculated based on unbound plasma bictegravir (Cmax × percentage unbound bictegravir ÷ 100 for each participant).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Bictegravir (Free)
ng/mLSevere Renal ImpairmentNormal Renal Function
PK Parameter: Cmax of Bictegravir (Free)37.7 ± 8.1535.0 ± 9.94
Statistical analysis
  • Severe Renal Impairment vs Normal Renal Function · Glsm ratio: 109.80 · 90% CI 87.46 to 137.85
SecondaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are defined as any adverse events (AEs) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

Time frame:
First dose date to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
percentage of participantsSevere Renal ImpairmentNormal Renal Function
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events20.025.0
SecondaryPercentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities

A treatment-emergent graded laboratory abnormality was defined as an increase of at least 1 abnormality grade from the predose assessment and occurring after the predose visit and on or before the date of the administration of study drug plus 30 days. The most severe graded abnormality from all tests was counted for each participant. Toxicity grade was defined as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, and Grade 4 = Life-threatening.

Time frame:
First dose date to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Laboratory Abnormalities
percentage of participantsSevere Renal ImpairmentNormal Renal Function
Grade 120.025.0
Grade 240.025.0
Grade 340.00
Grade 400

Adverse events

Collected over First dose date to Day 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Renal Impairment0/10 (0%)0/10 (0%)2/10 (20%)
Normal Renal Function0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Most frequent other events
EventSevere Renal ImpairmentNormal Renal Function
ConstipationGastrointestinal disorders0/101/8
HeadacheNervous system disorders0/101/8
NauseaGastrointestinal disorders1/100/8
Back painMusculoskeletal and connective tissue disorders1/100/8
EcchymosisSkin and subcutaneous tissue disorders1/100/8

Baseline characteristics

The Safety Analysis Set included participants who received the single dose of bictegravir.

Age, Continuous
Age, Continuous(years)Severe Renal ImpairmentNormal Renal FunctionTotal
Mean62 ± 15.656 ± 14.759 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)Severe Renal ImpairmentNormal Renal FunctionTotal
Female325
Male7613
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Severe Renal ImpairmentNormal Renal FunctionTotal
Hispanic or Latino325
Not Hispanic or Latino7613
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Severe Renal ImpairmentNormal Renal FunctionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White7714
More than one race000
Unknown or Not Reported000
08

Study locations

7 sites
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014-3616, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Prism Clinical Research
    Saint Paul, Minnesota 55114, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
  • Auckland Clinical Studies Limited
    Grafton, Auckland 1010, New Zealand
  • Christchurch Clinical Studies Trust
    Christchurch, 8011, New Zealand
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jul 2015, 2 months.

Results were first posted in Oct 2019, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2015
First posted
Mar 27, 2015
StartActual
Apr 17, 2015
Primary completionActual
Jul 6, 2015
CompletionActual
Jul 13, 2015
Results first posted
Oct 11, 2019
Last update
Oct 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02400307
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 27, 2015
Start date
Apr 17, 2015
Primary completion
Jul 6, 2015
Completion
Jul 13, 2015
Results posted
Oct 11, 2019
Last update
Oct 11, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bictegravir

Start the discussion